Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellpatients mustcellsor equalgreater
  Phrases that lowered it: safety ofliverallergyhepatitisclinical
• Sponsor's past termination rate: 28.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 326 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 71.4% (lowers risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 159 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Keywords listed: 26 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 16.3% (lowers risk) · Drug's FDA history
• Maximum age: 70 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 18332 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 92156 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies NCT01823198 · started 2013 · scored riskier than 91% of active trials completed
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia NCT01904136 · started 2014 · scored riskier than 47% of active trials completed
• A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias NCT01287104 · started 2011 · scored riskier than 38% of active trials completed
• Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01787474 · started 2014 · scored riskier than 94% of active trials completed
• Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML NCT04220684 · started 2020 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.